Heartflow has developed a web‐based technology that enhances a non‐invasive assessment of coronary blood flow and pathology. The technology is designed to guide physicians’ diagnostic decisions about coronary heart disease (“CHD”) and act as a treatment planning tool. This new technology could eliminate unnecessary diagnostic and therapeutic cardiac catheterizations and medication, thereby improving clinical care while eliminating billions in unnecessary spend. HeartFlow is based in Palo Alto, CA.